Risankizumab Noninferior, Superior to Ustekinumab for Crohn Disease
Risankizumab noninferior for clinical remission at week 24, superior for endoscopic remission at week 48
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.